Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers
Abstract Selective inhibition of the transcription elongation factor (P‐TEFb) complex represents a promising approach in cancer therapy, yet CDK9 inhibitors (CDK9i) are currently limited primarily to certain hematological malignancies. Herein, while initial responses to CDK9‐targeted therapies are o...
Saved in:
| Main Authors: | Yafang Wang, Lansong Xu, Lijun Ling, Mingyue Yao, Shangxuan Shi, Chengcheng Yu, Yingnian Li, Jie Shen, Hualiang Jiang, Chengying Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202404926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
by: Mohamed I Saad, et al.
Published: (2019-03-01) -
A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway
by: Runhui Lu, et al.
Published: (2025-01-01) -
ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
by: Chiara Pozzato, et al.
Published: (2024-09-01) -
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01) -
Computational screening of phytochemicals targeting mutant KRAS in colorectal cancer
by: Muskan Arooj, et al.
Published: (2025-08-01)